IRIS
DE LUCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.365
EU - Europa 21.332
AS - Asia 9.451
SA - Sud America 1.904
Continente sconosciuto - Info sul continente non disponibili 927
AF - Africa 548
OC - Oceania 54
Totale 63.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.915
GB - Regno Unito 5.878
IT - Italia 3.967
CN - Cina 3.105
RU - Federazione Russa 2.948
SG - Singapore 2.863
IE - Irlanda 2.460
UA - Ucraina 1.868
BR - Brasile 1.580
FR - Francia 1.196
VN - Vietnam 1.108
DE - Germania 972
HK - Hong Kong 926
SE - Svezia 890
FI - Finlandia 519
BD - Bangladesh 244
IN - India 239
ZA - Sudafrica 230
CA - Canada 228
KR - Corea 204
NL - Olanda 138
NG - Nigeria 134
ES - Italia 118
TR - Turchia 108
AR - Argentina 106
IQ - Iraq 96
MX - Messico 88
PK - Pakistan 73
AT - Austria 67
PL - Polonia 62
BE - Belgio 61
JP - Giappone 58
ID - Indonesia 51
CO - Colombia 50
VE - Venezuela 50
EC - Ecuador 42
IR - Iran 42
PH - Filippine 42
AU - Australia 41
SA - Arabia Saudita 34
KE - Kenya 31
MA - Marocco 31
MY - Malesia 31
UZ - Uzbekistan 29
CZ - Repubblica Ceca 28
CL - Cile 27
CR - Costa Rica 23
JO - Giordania 23
AE - Emirati Arabi Uniti 22
JM - Giamaica 22
KZ - Kazakistan 18
NP - Nepal 18
PT - Portogallo 17
PY - Paraguay 17
EG - Egitto 16
EU - Europa 16
GR - Grecia 16
IL - Israele 16
TT - Trinidad e Tobago 16
CH - Svizzera 15
HN - Honduras 14
TN - Tunisia 14
DZ - Algeria 13
ET - Etiopia 13
LT - Lituania 13
PE - Perù 13
LB - Libano 12
TH - Thailandia 12
UY - Uruguay 12
AL - Albania 11
AZ - Azerbaigian 11
CI - Costa d'Avorio 11
UG - Uganda 11
BG - Bulgaria 10
OM - Oman 10
PA - Panama 10
HU - Ungheria 9
NZ - Nuova Zelanda 9
PR - Porto Rico 9
SK - Slovacchia (Repubblica Slovacca) 9
EE - Estonia 8
PS - Palestinian Territory 8
SN - Senegal 8
DO - Repubblica Dominicana 7
KG - Kirghizistan 7
LV - Lettonia 7
AO - Angola 6
BB - Barbados 6
DK - Danimarca 6
GT - Guatemala 6
LU - Lussemburgo 6
TW - Taiwan 6
BS - Bahamas 5
LK - Sri Lanka 5
NI - Nicaragua 5
NO - Norvegia 5
RS - Serbia 5
SC - Seychelles 5
SV - El Salvador 5
AM - Armenia 4
Totale 62.579
Salva come PNG Salva come JPEG
Città #
Southend 5.243
Fairfield 2.919
Dallas 2.679
Ashburn 2.667
Dublin 2.442
Chandler 1.789
Jacksonville 1.530
Woodbridge 1.471
Singapore 1.394
Seattle 1.165
Wilmington 1.144
San Jose 1.113
Cambridge 1.024
Houston 1.020
Hong Kong 879
Milan 821
Santa Clara 749
Moscow 722
Council Bluffs 699
Beijing 670
Ann Arbor 645
Princeton 496
Munich 494
The Dalles 493
Nanjing 455
Menlo Park 453
Siena 422
Los Angeles 403
Rome 378
Helsinki 372
New York 338
Lauterbourg 301
Boardman 278
Ho Chi Minh City 270
Hanoi 248
Dong Ket 229
Seoul 198
Hefei 196
Johannesburg 181
São Paulo 172
San Diego 161
Buffalo 147
Nanchang 146
Shenyang 135
Columbus 126
Abuja 121
Redondo Beach 120
Dearborn 114
Turin 101
Tianjin 98
London 90
Changsha 89
Hebei 84
Figino 83
Bologna 81
Shanghai 78
Toronto 74
San Mateo 71
Jiaxing 68
Nuremberg 66
Orem 66
Chicago 64
Naples 63
Florence 62
Málaga 61
Phoenix 61
Frankfurt am Main 59
Brussels 53
Chennai 53
Kunming 52
Zhengzhou 51
Jinan 50
San Francisco 49
Tokyo 48
Norwalk 47
Guangzhou 46
Montreal 45
Ningbo 45
Atlanta 43
Izmir 42
Belo Horizonte 41
Brooklyn 41
Turku 41
Warsaw 41
Vienna 40
Da Nang 39
Düsseldorf 39
Rio de Janeiro 38
Genoa 37
Baghdad 36
Haiphong 36
Taizhou 35
Lancaster 33
Dhaka 32
Falls Church 30
Brasília 29
Stockholm 29
Denver 28
Washington 28
Tashkent 27
Totale 42.975
Salva come PNG Salva come JPEG
Nome #
Utilizzo di dalbavancina nella terapia delle infezioni osteoarticolari 1.472
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: Implications for the activity of next-line regimens from a longitudinal study in Mozambique 672
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 650
UTILIZZO DI MILTEFOSINA IN PAZIENTE CON LEISHMANIOSI MUCOSA ED INFEZIONE DA HIV 614
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 598
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 584
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 508
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study 404
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. 390
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 377
ERITEMA NODOSO RECIDIVANTE E PERSISTENTE REPLICA DI EPSTEIN-BARR VIRUS 371
An outbreak of HIV-1 subtype G among Italian injecting drug users 360
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 358
Non-granulomatous cerebellar infection by Acanthamoeba spp. in an immunocompetent host 340
Analisi retrospettiva su infezioni invasive e non invasive da batteri Gram negativi non fermentanti in pazienti ospedalizzati 329
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 328
Nuovi approci diagnostici nelle infezioni pneumococciche: possibile ruolo della Real-time PCR e dei biomarcatori 324
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 322
A novel methodology for large-scale phylogeny partition 317
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 313
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 310
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 309
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 307
Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes 307
HCMV infection in renal transplant recipients: a retrospective cohort study 302
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 299
Evolution of macrolide resistance in streptococcus pyogenes over 14 years in an area of central Italy 298
Case Report: Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy 297
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 294
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 293
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 293
Sieroprevalenza di HEV in donatori di sangue e pazienti trapiantati di rene nella provincia di Siena. 292
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 291
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 291
Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy [Sieroprevalenza dell’infezione da virus dell’epatite E (HEV) in donatori di sangue e pazienti trapiantati di rene: Uno studio retrospettivo dal centro Italia] 288
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 284
Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy 283
Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature 277
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 275
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 275
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 271
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 271
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 269
Diagnosi di sarcoidosi in nuova diagnosi di HIV 259
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 257
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 257
Risposta immunitaria a lungo termine dopo vaccinazione antipneumococcica con vaccino coniugato 13-valente o vaccino polisaccaridico 23-valente in adulti HIV positivi 253
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study 253
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 252
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. 250
FIBRILLO-FLUTTER IN ASSENZA DI SEGNI DI MIOCARDITE IN CORSO DI INFEZIONE DA EBV 249
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 249
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 248
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 244
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 242
Valutazione della risposta al test IGRA in pazienti pediatrici contatto di TBC o con sospetto clinico di infezione attiva 239
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 235
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 235
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 234
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 234
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 233
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 232
Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion 231
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 230
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 229
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 228
233. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. 227
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 227
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 227
Prevalence of M75 Streptococcus Pyogenes strains harboring slaa gene in patients affected by pediatric obstructive sleep apnea syndrome in Central Italy 227
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype 225
European guidelines on the clinical management of HIV-1 tropism testing 225
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 224
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 223
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 221
Evoluzione ed efficace controllo di un vasto focolaio epidemico nosocomiale da Klebsiella pneumoniae produttrice di carbapenemasi in un’area Neurochirurgica: lezioni apprese. 219
Un raro caso di osteomielite da Moraxella osloensis e Staphylococcus capitis in giovane paziente immunocompetente 217
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 216
LA MALATTIA PNEUMOCOCCICA IN ETÀ PEDIATRICA: CONFRONTO FRA EPOCA PRE- E POST-VACCINALE 215
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load 214
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 212
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 208
Gastroenteritis and Intractable Diarrhea in Newborns 208
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy RID G-8810-2011 RID A-1577-2008 206
Meningite purulenta a decorso atipico in età pediatrica 205
La diagnosi eziologica della polmonite comunitaria: possibile ruolo della Real-Time PCR in una coorte di pazienti adulti e pediatrici 205
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 205
A whole-genome association study of major determinants for host control of HIV-1 RID A-6681-2009 RID A-2073-2010 RID B-5656-2009 RID F-2587-2010 RID G-8810-2011 202
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 202
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 201
Tubercolosi e "pregiudizio epidemiologico": diagnosi invasiva di sarcoidosi necrotizzante in giovane immigrato 201
Long-term immune response to 13-valent Pneumococcal Conjugate Vaccine versus 23-valent Polysaccharide Vaccine in HIV-1 infected adults 200
"Buffalo hump" in HIV-1 infection RID G-8810-2011 199
Alveolar macrophages from AIDS patients spontaneously produce elevated levels of TNF-alpha in vitro. 197
Una recidiva di endocardite di difficile diagnosi 196
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 196
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 195
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. 195
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 195
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 193
Totale 29.008
Salva come PNG Salva come JPEG
Categoria #
all - tutte 195.685
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 195.685
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.766 0 0 0 282 137 167 169 184 213 432 348 834
2022/20235.735 371 308 592 893 675 1.267 76 463 625 136 170 159
2023/20243.659 197 120 282 146 149 865 1.209 119 27 111 144 290
2024/20257.635 230 493 589 422 676 439 450 608 775 339 783 1.831
2025/202616.236 1.193 2.224 1.733 1.404 2.876 748 2.150 550 543 839 469 1.507
2026/20273.946 700 568 1.568 1.110 0 0 0 0 0 0 0 0
Totale 63.581